In December 2018, my term as editor of the Journal of Cardiovascular Pharmacology will come to a close. I have been asked by some why I did not request to stay on and the response is simple: any journal should be bigger than the individual editor, and just as editors may grow old and fixed in their views, so may journals suffer by being led too long by those too long in the tooth. And so, I will pack up my teeth and move onward.
Overall, I am happy with the progress the journal has made since I started my term in 2007. The impact factor has more than doubled—although it still has a way to go; the papers submitted continue to come from a broad international set of authors; we have contributed our small bit to the preservation of the environment by going entirely digital in our publication. The focused review series has been a major success, mainly thanks to the efforts of Steve Feinmark, and the Drugs in the Pipelines series—conceived of by George Booz—has been a notable success as well.
Although an editor is usually given the credit for the success of a journal, it is never that simple. In fact, the current situation of this Journal owes a great deal to the efforts of the associate editors—Steve Feinmark, Susan Steinberg, and George Booz, to all of whom I give my thanks. A vote of thanks, as well, to my friend and predecessor, Paul Vanhoutte, who has contributed in so many ways to the success of the Journal over the years, preceding me as editor in chief and then taking over the Supplements. Doug Zipes has been an invaluable Consulting Editor, managing those manuscripts where conflicts of interest prevented the in-house editorial staff from handling the review process. And the members of the Editorial Board have been staunch supporters of the Journal and have seen to it that reviews for the most part are processed within 2 weeks of the time of submission.
I have not yet mentioned 2 people whose efforts have been critical to our success. One is Cordelia Slaughter, our publisher, who has been very much hands-on in ensuring that the relationship with our parent, Kluwer, has been completely supportive and smooth. The other is Emily Hurd, our managing editor and who I believe at times may be my boss in informing me gently that something should or should not be done, and in ensuring the entire operation from submission through review, decision-making, and publication of manuscripts runs smoothly. I will miss hearing Cordelia's and Emily's voices on our monthly conference calls dealing with the varied issues that come up in journal management and publication.
As I move on, I know that the Journal will be in excellent hands with the new Editor, George Booz, aided by Drs Feinmark and Steinberg who will remain as associate editors, at least for the time being. Dr Booz has several initiatives he is planning for the Journal, which I will leave for him to describe to you. The transition period began on July 1 and will be completed by December 31, at which time I will be permitted to fade into the sunset, which I have every intention of doing.
In closing, my thanks again to all… it has been a pleasure to serve during this period and I look forward to the continued and greater success of the Journal.